Raymond James Financial
MEDS

Raymond James Financial’s DataMeds AI MEDS Stock Holding History

Raymond James Financial’s Portfolio MEDS Stock Details MEDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,168
Closed -$5.63K – 5616
2026
Q1 		$5.63K Hold
1,168
– – ﹤0.01% 5269
2025
Q4 		$23.3K Hold
1,168
– – ﹤0.01% 5077
2025
Q3 		$51.8K Buy
1,168
+1,000
+595% +$52.8K ﹤0.01% 4819
2025
Q2 		$8.16K Buy
+168
New +$23.2K ﹤0.01% 6001

Other funds holding MEDS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Raymond James Financial's MEDS Position: Q2 2026 in Review

Raymond James Financial sold out of DataMeds AI (MEDS) in Q2 2026, closing a stake of 1,168 shares — an estimated $5.63K sold.

Raymond James Financial first reported a position in MEDS in Q2 2025 and held it in 4 quarters. The position peaked at $51.8K in Q3 2025. 9 funds tracked by Wall St. Rank hold MEDS as of Q2 2026.

  • Raymond James Financial reported no remaining DataMeds AI position as of Q2 2026 after selling out during the quarter.
  • Raymond James Financial sold 1,168 DataMeds AI shares in Q2 2026, an estimated $5.63K.
  • Raymond James Financial first reported a position in DataMeds AI in Q2 2025 and held it in 4 quarters.
  • Raymond James Financial's DataMeds AI position peaked at $51.8K in Q3 2025.
  • 9 funds tracked by Wall St. Rank held DataMeds AI as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.